Search: onr:"swepub:oai:DiVA.org:liu-16848" >
Phosphorylation of ...
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer
-
- Holm, C (author)
- Lund University
-
- Kok, M (author)
- Netherlands Cancer Institute
-
- Michalides, R (author)
- Netherlands Cancer Institute
-
show more...
-
- Fles, R (author)
- Netherlands Cancer Institute
-
- Koornstra, R H T (author)
- Netherlands Cancer Institute
-
- Wesseling, J (author)
- Netherlands Cancer Institute
-
- Hauptmann, M (author)
- Netherlands Cancer Institute
-
- Neefjes, J (author)
- Netherlands Cancer Institute
-
- Peterse, J L (author)
- Netherlands Cancer Institute
-
- Stål, Olle (author)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
-
- Landberg, Göran (author)
- Lund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups
-
- Linn, S C (author)
- Netherlands Cancer Institute
-
- Wigerup, Caroline (author)
- Lund University,Lunds universitet,Patologi, Malmö,Forskargrupper vid Lunds universitet,Pathology, Malmö,Lund University Research Groups
-
show less...
-
(creator_code:org_t)
- Wiley, 2009
- 2009
- English.
-
In: JOURNAL OF PATHOLOGY. - : Wiley. - 0022-3417 .- 1096-9896. ; 217:3, s. 372-379
- Related links:
-
http://www.ncbi.nlm....
-
show more...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- Phosphorylation of oestrogen receptor a at serine 305 (ER alpha S305-P) induces tamoxifen resistance in experimental studies, but does not influence response to other endocrine agents, such as fulvestrant. We evaluated ER alpha S305-P using immunohistochemistry in 377 breast carcinomas from premenopausal participants of a randomized trial (n = 248) and patients with advanced disease (n = 129). Among the premenopausal patients, adjuvant tamoxifen improved recurrence-free survival (RFS) for ER alpha S305-P-negative tumours (multivariate HR = 0.53, 95% CI 0.32-0.86, p = 0.010), but not for ER alpha S305-P-positive tumours (multivariate HR = 1.01, 95% CI 0.33-3.05, p = 0.99) (interaction p = 0.131). Notably, ER alpha S305-P was not significantly associated with RFS in patients not treated with tamoxifen (multivariate HR = 0.64, 95% CI 0.30-1.37, p = 0.248), indicating that ER alpha S305-P is a marker for treatment outcome rather than tumour progression. Given the direct experimental link between ER alpha S305-P and tamoxifen resistance and these first clinical data suggesting that premenopausal patients with ER alpha S305-P-positive breast cancer are resistant to adjuvant tamoxifen, further research is encouraged to study whether alternative endocrine treatment should be considered for this subgroup.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)
Keyword
- breast
- breast cancer
- immunohistochemistry
- oestrogen receptor
- phosphorylation
- tamoxifen
- drug resistance
- predictive marker
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Holm, C
-
Kok, M
-
Michalides, R
-
Fles, R
-
Koornstra, R H T
-
Wesseling, J
-
show more...
-
Hauptmann, M
-
Neefjes, J
-
Peterse, J L
-
Stål, Olle
-
Landberg, Göran
-
Linn, S C
-
Wigerup, Carolin ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Cell and Molecul ...
- Articles in the publication
-
JOURNAL OF PATHO ...
- By the university
-
Linköping University
-
Lund University